Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Study Summary

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Conditions

Metastatic Hepatocellular Carcinoma Solid Tumors Solid Tumor, Adult FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation Advanced Solid Tumors FGFR4 Gene Mutation FGFR4 Gene Fusions FGF19 Gene Amplification FGF19 Gene Overexpression FGFR3 Gene Fusions Locally Advanced Unresectable Hepatocellular Carcinoma

Interventions / Drugs

TYRA-430

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment100 participants

Primary Completion—

Lead SponsorTyra Biosciences, Inc

Data Retrieved2026-04-11 04:30:22.593358+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.